FIELD: biotechnology.
SUBSTANCE: invention relates to the biotechnology. Described is an oligonucleotide miR-155 inhibitor containing/consisting of sequence (s) and 5’-lCs.dAs.lCs.dGs.dAs.lTs.lTs.dAs.lGs.dCs.lAs.lTs.lTs.lA-3’ (SEQ ID NO: 25), where l is a closed nucleotide; d is a deoxyribonucleotide; s is a phosphorothioate bond or an oligonucleotide miR-155 inhibitor containing/consisting of sequence(s) and 5’-lCs.dAs.lCs.dGs.dAs.lTs.lTs.dAs.lGs.lCs.dAs.lTs.lTs.lA-3’ (SEQ ID NO: 53), where l is a closed nucleotide; d is a deoxyribonucleotide; s is a phosphorothioate linkage.
EFFECT: invention can be used for treating a malignant tumour, such as T-cell lymphoma; and can also be used to reduce or inhibit malignant T-cell proliferation.
34 cl, 28 dwg, 14 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF RECOMBINANT AAV AND USE THEREOF | 2015 |
|
RU2738421C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING microRNA-100 AND USE THEREOF IN MODULATING GROWTH OF BLOOD VESSELS AND ENDOTHELIUM INFLAMMATION | 2010 |
|
RU2586531C2 |
| DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES | 2010 |
|
RU2515926C2 |
| ONCOLYTIC VIRAL VECTORS AND THEIR APPLICATION | 2018 |
|
RU2771110C2 |
| ANTICANCER RNA VACCINES | 2017 |
|
RU2768829C2 |
| OLIGODENDROCYTE-SPECIFIC PROMOTOR, microRNA SPECIFIC TO PLP1 GENE, VECTOR CONTAINING SPECIFIED PROMOTOR AND/OR SPECIFIED microRNA, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED VECTOR | 2019 |
|
RU2788605C2 |
| REGULATION OF METABOLISM USING MIR-378 | 2011 |
|
RU2585491C2 |
| POLYNUCLEOTIDES CODING INTERLEUKIN-12 (IL12), AND APPLICATIONS THEREOF | 2017 |
|
RU2769316C2 |
| CANCER IMMUNOTHERAPY | 2014 |
|
RU2744194C2 |
| DOUBLE-STRANDED RNA MOLECULE FOR MIR-34A ACTIVITY IN CELL | 2012 |
|
RU2615117C2 |
